



### Minimal Datasets:

We are aiming to publish the ICARUS Baseline data imminently, followed closely by the Post Vaccination Data.

We would kindly like to ask for those sites who have opted to provide participant clinical data using our minimal dataset template, to please send your dataset for the **post vaccination analysis** (timepoint 2) by **Wednesday 20<sup>th</sup> April**.

### Publications

The ICARUS recent submission of *'Increased socio-economic deprivation, and younger age are key determinants of reduced rates of uptake of the third dose of SARS-CoV-2 vaccines among patients with inflammatory bowel disease on biological therapy'* was published in The Lancet Gastroenterology & Hepatology on 6<sup>th</sup> April. Please see attached.

I have also attached a paper published by the CLARITY IBD Study which may be of interest to you, *'Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab'*.

### 2 Year Extension Proposal:

Final edits are currently being made to the 2-year extension proposal. We are aiming to submit this to The Helmsley Trust before the Easter holidays.

The research will be completed at a subset of sites from the initial data collection period. **All seropositive patients, plus a cohort of matched controls** (by centre, age, sex, IBD-diagnosis, and medication), will be eligible for continued participation.

Participants will be assessed at t = 0 during the first infusion after the continuation begins in Spring 2022, and then again at 6 months, 12 months, 18 months, and 24 months.

**At each timepoint, surveys and blood specimens will be collected**, processed, banked, and analysed. Other samples, including biopsies, will be collected when the procedures are clinically indicated for the patient.